Formulation: A solid
Formal Name: (3β,5β,12β)-3-[(O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide-21,21,22-d3
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C41H61D3O14
Formula Weight: 784
Shelf life (days): 1460
CAS Number: 127299-95-0
Notes: Digoxin-d3 is intended for use as an internal standard for the quantification of digoxin (Item No. 22266) by GC- or LC-MS. Digoxin is a cardiac glycoside and metabolite of digitoxin (Item No. 27825) that binds to and inhibits the Na+/K+-ATPase in cardiac tissues in an ATP- and Mg2+-dependent manner.{38192} This inhibition results in loss of the transmembrane Na+ gradient, which decreases activity of the Na+/Ca2+ exchanger, increasing intracellular Ca2+ levels, inotropy, and cardiac force.{38193} It increases activity of mitochondrial ATPase and actomyosin ATPase in rat hearts, which is directly correlated with increased myofibrillar contractile strength.{38194} In vivo, digoxin also decreases right atrial pressure and increases cardiac output in a canine model of congestive heart failure produced by pulmonary artery constriction.{38195} Formulations containing digoxin have been used to treat atrial fibrillation.{38196}
English
Deutsch
